In addition to drug products based on our proprietary delivery technology, we have a portfolio of generic product candidates with favorable commercial agreements that supplement our branded pipeline.
In Market
acyclovir cream, 5%
(RLD: ZOVIRAX®)
Sales as of
January 2019
Pending
ivermectin cream, 1%
(RLD: SOOLANTRA®)
Tentative Approval
as of January 2019
5-fluorouracil cream, 5%
(RLD: EFUDEX®)
Bioequivalence
Study Completed
Additional R&D
In addition to advancing our lead product candidates, we are also engaged in the formulation and pre-clinical development of early-stage innovative product candidates for both current indications, such as acne and rosacea, and for other dermatological indications.
All trademarks are the properties of their prospective owners.